DCM
VIRX

Decade Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Decade Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,176
Closed -$2.17M – 253
2013
Q4 		$2.17M Sell
2,176
-437
-17% -$452K 0.16% 110
2013
Q3 		$2.72M Buy
+2,613
New +$2.79M 0.16% 110

Other funds holding VIRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Decade Capital Management's VIRX Position: Q1 2014 in Review

Decade Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2014, closing a stake of 2,176 shares — an estimated $2.17M sold.

Decade Capital Management first reported a position in VIRX in Q3 2013 and held it in 2 quarters. The position peaked at $2.72M in Q3 2013. 95 funds tracked by Wall St. Rank hold VIRX as of Q1 2014.

  • Decade Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2014 after selling out during the quarter.
  • Decade Capital Management sold 2,176 Viracta Therapeutics, Inc. Common Stock shares in Q1 2014, an estimated $2.17M.
  • Decade Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2013 and held it in 2 quarters.
  • Decade Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $2.72M in Q3 2013.
  • 95 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2014.

Based on Decade Capital Management's 13F filing for Q1 2014, filed 15 May 2014.